XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
US Stock MarketDetailed Quotes
SLRN Acelyrin
- 2.130
- +0.070+3.40%
Close Feb 14 16:00 ET
- 2.110
- -0.020-0.93%
Post 20:01 ET
213.69MMarket Cap-0.80P/E (TTM)
2.140High2.050Low2.34MVolume2.050Open2.060Pre Close4.92MTurnover3.88%Turnover RatioLossP/E (Static)100.33MShares8.88552wk High0.40P/B128.27MFloat Cap1.84552wk Low--Dividend TTM60.22MShs Float29.880Historical High--Div YieldTTM4.37%Amplitude1.845Historical Low2.107Avg Price1Lot Size
Acelyrin Stock Forum
Sign in to post a comment
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow...
59
8
3
$Acelyrin (SLRN.US)$
Based on the provided information, Alumis Inc. (ALMS) and ACELYRIN, Inc. (SLRN) have announced a merger agreement. In this all-stock transaction, ACELYRIN stockholders will receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock they own. Post-merger, Alumis stockholders will own approximately 55% of the combined company, while ACELYRIN stockholders will own about 45% on a fully diluted basis. 
Estimating the Post-Merger Stock Price of Alu...
Based on the provided information, Alumis Inc. (ALMS) and ACELYRIN, Inc. (SLRN) have announced a merger agreement. In this all-stock transaction, ACELYRIN stockholders will receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock they own. Post-merger, Alumis stockholders will own approximately 55% of the combined company, while ACELYRIN stockholders will own about 45% on a fully diluted basis. 
Estimating the Post-Merger Stock Price of Alu...
1
$Acelyrin (SLRN.US)$ $Alumis (ALMS.US)$ Reuters· 3 mins ago
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-Mediated Diseases
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-Mediated Diseases
6
$Acelyrin (SLRN.US)$ $Alumis (ALMS.US)$
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Thursday, 6th February at 4:15 pm
Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout i...
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Thursday, 6th February at 4:15 pm
Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout i...
3
8
1
$Acelyrin (SLRN.US)$ it's not even a negative update. dropping for what
3
$Acelyrin (SLRN.US)$ Reuters· 1 min ago
ACELYRIN Inc - Lonigutamab Shows Potential Efficacy and Favorable Safety Profile in Ted
ACELYRIN Inc - Lonigutamab Shows Potential Efficacy and Favorable Safety Profile in Ted
$Acelyrin (SLRN.US)$
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
Thursday, 2nd January at 8:00 pm
LOS ANGELES, Jan. 02, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a virtual investor event on Monday, January 6, 2025 at 4:30 PM ET to pro...
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
Thursday, 2nd January at 8:00 pm
LOS ANGELES, Jan. 02, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a virtual investor event on Monday, January 6, 2025 at 4:30 PM ET to pro...
2
No comment yet
Trending Stocks
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
HannChau : I will not be silent stalker but always will be voice out 'stalker'![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Best Yavo : can I ask what time frames do u look at when trading?
Jaguar8 OP Best Yavo : 1,3,5,15 for active trades
Best Yavo : thank you
MilaDing Best Yavo : When do you usually release Watchlist information?
View more comments...